Photo: Alamy
The White House on Thursday unveiled TrumpRx.gov, a new government-hosted website that officials say will help Americans locate lower-cost prescription drug options.
The site does not sell medications directly. Instead, it directs users to pharmaceutical manufacturers that offer direct-to-consumer discounts and online purchasing programs.
White House press secretary Karoline Leavitt announced the launch on social media, calling TrumpRx “a state of the art website for American consumers to purchase low cost prescription drugs.”
President Trump introduced the site alongside Dr. Mehmet Oz, administrator of the Centers for Medicare & Medicaid Services, and Joe Gebbia, director of the White House National Design Studio.
Administration officials said TrumpRx is designed to function as a directory, linking consumers to manufacturers’ own discount platforms and online storefronts where eligible prescriptions can be purchased outside traditional pharmacy benefit channels.
The rollout follows months of anticipation. Trump previewed the initiative last September as part of a broader push to reduce prescription drug costs, an issue that continues to rank high among voter concerns.
The White House has promoted the site to improve price transparency and reduce the role of intermediaries. However, officials acknowledge that savings will vary, particularly for Americans who already receive prescription coverage through employers, private insurance, Medicare or Medicaid.
President Trump has also highlighted separate agreements with pharmaceutical companies that aim to reduce prices on selected drugs by tying them to the lowest prices offered in other developed nations, an approach the administration describes as “most favored nation” pricing.
Some newly launched drugs are expected to be available through manufacturer platforms accessible via TrumpRx links, according to officials, though details on which medications qualify and how eligibility will be verified have not been fully disclosed.
Health policy experts note that manufacturer cash prices can sometimes be lower than retail list prices, particularly for uninsured patients or those facing high cost-sharing. Still, they caution that direct-to-consumer discounts will not always beat negotiated insurance rates, especially for people in plans with strong pharmacy benefits.